MGMT Methylation Status in Grades 2 and 3 Gliomas Is Important, but Is It Prognostic?
Menée à partir de données portant sur 411 patients atteints d'un gliome anaplasique ou de bas grade (âge moyen : 44 ans ; 58 % d'hommes), cette étude met en évidence une association entre le statut de méthylation du promoteur du gène de la méthyltransférase MGMT et la survie après une chimiothérapie alkylante
Historical methods for diagnosing gliomas, which relied solely on histological features, led to heterogenous groups of tumors being classified similarly and were unreliable in determining patient outcomes. In 2016, a paradigm shift occurred when the World Health Organization (WHO) changed its classification system for gliomas to include molecular characteristics. Isocitrate dehydrogenase (IDH) 1 or 2 variant status and 1p/19q chromosomal codeletion were reflected in this reclassification. Further regrouping of gliomas based on molecular classification was done in the WHO 2021 update. While it is common to request O6-methylguanine–DNA methyltransferase (MGMT) methylation status for glial tumors, to our knowledge it is not currently used for molecular classification.
JAMA Oncology , éditorial, 2022